Baldwin Wealth Partners LLC MA Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

Baldwin Wealth Partners LLC MA increased its position in Zoetis Inc. (NYSE:ZTS) by 5.6% in the fourth quarter, Holdings Channel reports. The firm owned 74,961 shares of the company’s stock after purchasing an additional 4,002 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Zoetis were worth $12,213,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Darwin Wealth Management LLC acquired a new position in shares of Zoetis in the 3rd quarter worth approximately $31,000. First Personal Financial Services acquired a new position in Zoetis in the third quarter worth $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis during the third quarter valued at $33,000. Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares during the last quarter. Finally, Quarry LP boosted its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the period. 92.80% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on ZTS shares. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Finally, Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $211.89.

Zoetis Trading Up 1.6 %

Shares of ZTS opened at $171.32 on Monday. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The business’s 50-day moving average price is $170.10 and its 200 day moving average price is $179.75. The stock has a market capitalization of $77.30 billion, a P/E ratio of 32.16, a P/E/G ratio of 2.57 and a beta of 0.89. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the firm earned $1.36 EPS. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. Analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. Zoetis’s payout ratio is currently 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.